What is Swedish Orphan Biovitrum AB Current Ratio?
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Swedish Orphan Biovitrum AB's current ratio for the quarter that ended in Mar. 2024 was 0.71.
Swedish Orphan Biovitrum AB has a current ratio of 0.71. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If Swedish Orphan Biovitrum AB has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.
The historical rank and industry rank for Swedish Orphan Biovitrum AB's Current Ratio or its related term are showing as below:
SWTUY'
s Current Ratio Range Over the Past 10 Years
Min: 0.59 Med: 1.16 Max: 2.83
Current: 0.71
During the past 13 years, Swedish Orphan Biovitrum AB's highest Current Ratio was 2.83. The lowest was 0.59. And the median was 1.16.
SWTUY's Current Ratio is ranked worse than 86.06% of 1076
companies
in the Drug Manufacturers industry
Industry Median: 1.88
vs SWTUY: 0.71
Swedish Orphan Biovitrum AB Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Swedish Orphan Biovitrum AB's Current Ratio
For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Swedish Orphan Biovitrum AB's Current Ratio Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's Current Ratio distribution charts can be found below:
* The bar in red indicates where Swedish Orphan Biovitrum AB's Current Ratio falls into.
Swedish Orphan Biovitrum AB Current Ratio Calculation
The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Swedish Orphan Biovitrum AB (OTCPK:SWTUY) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Swedish Orphan Biovitrum AB Current Ratio Related Terms
Thank you for viewing the detailed overview of Swedish Orphan Biovitrum AB's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Swedish Orphan Biovitrum AB (Swedish Orphan Biovitrum AB) Business Description
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) on long-acting hemophilia factor replacement programs in 2006. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016. Sobi has since been building its immunology pipeline (rare disease drug Gamifant, U.S. rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and hematology pipeline outside of hemophilia (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).
Swedish Orphan Biovitrum AB (Swedish Orphan Biovitrum AB) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SWTUY has been successfully added to your 